Latest News
-
Thursday - December 18, 2008
Study presented of diabetes technology society meeting finds in-office A1CNow+ monitor demonstrates precision and accuracy in A1C testing
-
Tuesday - December 16, 2008
Milestone in the expansion of Bayer’s global trait activities:
Bayer CropScience launches herbicide-tolerance technology for soybeans in the United States
Market launch in 2009
-
Tuesday - December 16, 2008
BayVision® – Automotive glazing made of polycarbonate
All the intensity of a race car
Wind deflector of the KTM X-Bow made of Makrolon® AG2677
-
Friday - December 12, 2008
Bayer's Perspective on Innovation 2008
-
Friday - December 12, 2008
Online analytics for the biopharmaceutical industry
Bayer Technology Services and innovatis AG sign marketing&sales agreement
New BaychroMAT(R)-bioplatform expands innovatis product portffolio
-
Thursday - December 11, 2008
BayVision on course for success
New Bayer MaterialScience brand for polycarbonate glazing in automotive engineering
-
Wednesday - December 10, 2008
Wrinkle-free polyurethane skin for service robots:
Bayer MaterialScience wins FSK's prize for innovation
-
Wednesday - December 10, 2008
BaySystems to support Polio Eradication Program in India
Customized solution for safe and hygienic storage of vaccines
-
Wednesday - December 10, 2008
BayVision® – Polycarbonate automotive glazing
Realistic abrasion test in an automatic car wash
Pure wetcoats are more resistant than wetcoats with a plasma topcoat
-
Monday - December 8, 2008
Brochure on climate change and the Group’s Climate Program published:
Bayer: Integrated measures for increased climate protection
Approaches to the issue in the fields of construction, agriculture and production
-
Monday - December 8, 2008
Venous Blood Clot Prevention after Knee or Hip Replacement Surgery:
Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin
-
Friday - December 5, 2008
Daniel Hartert to be new Executive Board Chairman of Bayer Business Services GmbH
-
Thursday - December 4, 2008
Bayer expands men’s healthcare portfolio
Licence agreement for innovative testosterone gel also covers emerging markets
-
Friday - November 28, 2008
Customer symposium on innovations for special-purpose and commercial vehicle technology
On the fast track with BaySystems
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection
